- Indication: Systemic Sclerosis
- Enrollment Status: Pre-Enrollment
- Protocol: CVAY736S12201
- Drug: Ianalumab
- Sponsor: Novartis
- Description: A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
